The Mindich Child Health and Development Institute develops initiatives to further its mission of facilitating translational research of diseases affecting infants, children, and adolescents. 

Center for Child Health Services Research

We are pleased to announce that Dr. Brett R. Anderson, MD, MBA, MS has joined Mount Sinai as the inaugural Director for the Center for Child Health Services Research in the Mindich Child Health and Development Institute at the Icahn School of Medicine.

Dr. Anderson is a pediatric cardiologist and NIH-funded health services researcher, who blends her medical, business, and statistical backgrounds to bring together interdisciplinary investigators and data for the purposes of identifying modifiable drivers of outcomes, value, and health inequities, with a particular focus on children with cardiac disease. She has examined the effects of provider characteristics, surgical timing, social determinants of health, and various measures of healthcare access. She is the founder and Director of the New York State Congenital Heart Surgery Collaborative for Longitudinal Outcomes and Utilization of Resources (CHS-COLOUR), an interdisciplinary collaborative that brings together leadership and data from all congenital heart surgical centers in New York State, health services researchers, and the Department of Health, to examine etiologies of health inequities and to plan for programmatic interventions. Dr. Anderson completed her general pediatrics residency at The Children’s Hospital of Philadelphia and fellowship in pediatric cardiology at NewYork-Presbyterian/Morgan Stanley Children’s Hospital, prior to joining Columbia University Irving Medical Center's faculty in 2013. Dr. Anderson joins us after a decade at Columbia, where she served as Director of Clinical Research, Outcomes, and Quality for the Pediatric Heart Center and Co-Director of ASPIRE! Peer Mentoring.
The new Center for Child Health Services Research will serve as the primary locus for research on the healthcare system for children at The Icahn School of Medicine. The Center seeks to promote the sharing of interdisciplinary ideas, methodologies, data, and mentorship, to enhance productivity and creativity for investigators—both within and outside the Center. Partnering with existing departments, institutes, and governmental agencies, the Center's expertise will focus on improving the quality and effectiveness of the healthcare system for all children, with particular emphasis on: Providers, Payers, & Policy; Value & Effectiveness; and Access & Equity

Pediatric Precision Medicine Initiative

The Mindich Child Health and Development Institute (MCHDI) is proud to announce the launch of the Mount Sinai Pediatric Precision Medicine Initiative. At Mount Sinai, the strong commitment to developing scientific infrastructure for genomic technology and precision medicine has positioned our institution to lead the nation in applying state-of-the-art genomic research methodology to advancing patient care. This new initiative will bring together Mount Sinai care providers and investigators with diverse expertise throughout the Departments of Pediatrics and Genetics and Genomic Sciences, as well as the Icahn Institute for Genomics and Multiscale Biology, the Charles Bronfman Institute for Personalized Medicine, and the Precision Immunology Institute.

Precision medicine (PM) uses individualized patient data to accurately and rapidly diagnose disease, better predict the outcomes of medical issues, and treat illnesses more precisely and effectively. Currently, medical problems with strong genetic underpinnings such as birth defects, neurodevelopmental delays, and inborn errors of immunity are ones that typically manifest during infancy, childhood and/or adolescence, and where a PM approach can be transformative. Moreover, these types of conditions can lead to diagnostic odysseys, during which young patients are subjected to extensive medical testing for months or years, families wait anxiously for definitive answers, and effective therapies, when available, are delayed. Through the MCHDI’s exciting new Pediatric Precision Medicine Initiative, we will improve outcomes by applying state-of-the-art genomic technologies as early as possible in the course of a child’s disorder.

Recent advances in genomic medicine have enabled the PM approach that we will undertake. Using just a few drops of blood from the child, we are able to perform high-capacity DNA sequencing to examine the genes that provide instructions for all of the body’s proteins. Especially when compared to similar sequencing of the patient’s parents in order to identify the rare differences, our ability to pinpoint disease-causing DNA mutations is unparalleled in medical history. To date, our experiences have proven that this approach can solve medical mysteries, identifying known disease genes presenting in unexpected ways as well as allowing us to pinpoint novel ones.

We are offering this PM approach to infants, children, and teenagers with some of the most complex and difficult-to-diagnose medical issues. In addition to accelerating and improving their care, this program will advance medical education by preparing the young physicians in pediatric training at Mount Sinai to use genomic medicine effectively, allowing them to better serve the community in their future practices.

Pediatric Clinical Trials Office

Clinical Trials are the final step that is required to prove that a therapeutic method can work in humans. Most such trials are done in adults, but the results of trials in adults are not necessarily entirely applicable to children. Pediatric clinical trials are therefore required to evaluate the efficacy of therapeutic or diagnostic strategies in pediatric populations, and the conduct of such trials has long been recognized as a priority by regulatory and funding agencies. However, conducting clinical trials in children necessitate specific approaches to study design and conduct that require special expertise. For example: the approach to consent is different (consent is required from the parents, and an assent, which is not a full consent, is required of children – depending on the age and cognitive ability), study design and processes may be quite different in different developmental stages, medication doses are calculated per patient/ patient characteristics (e.g., body mass index) rather than kept as a constant, and so on. It is furthermore recognized that patient recruitment to pediatric trials could be more complicated and that because pediatric diseases are generally less common, trials are likely to involve multisite designs.

For those reasons, MCHDI leadership decided to create a clinical trials program that will serve the needs of researchers within the Mount Sinai health system who wish to conduct pediatric clinical trials. The program will offer expertise in regulatory, budgeting, and operations of trials that involve children and families. We have partnered with the Clinical Trials Office (CTO) in Internal Medicine to provide this unique service which would offer its services to existing and “in development” trials, whether they involve investigator-initiated, industry-funded, or federally funded efforts. Under the support and supervision of the CTO Director, MCHDI leadership, and a dedicated group of pediatric investigators who are already successfully engaged in clinical trials research, a program manager will be charged with creating an operational team that will provide knowledgeable, efficient and convenient support to our diverse initiatives (which have been run in separate silos up until now).

Our vision is to enhance and expand current efforts, allow the development of future ideas and initiatives, reduce the startup costs and time-to-implementation of novel therapeutics, while promoting a collaborative multidisciplinary research enterprise in order to improve the health and quality of life of children.

Functional Genomics and Disease Modeling Core

This core studies rare Mendelian and genetic diseases and is co-sponsored by the MCHDI and the Department of Cell, Developmental & Regenerative Biology. By using Drosophila disease models, it provides an integrated cellular signaling analysis, high-throughput whole animal drug screens, and functional genomic modifier analysis, aiming to better understand disease and identify therapeutics. This functional genomics approach aims to integrate mechanism-based understandings of disease with existing and novel therapeutics.